You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Litigation Details for Edge Systems LLC v. Cartessa Aesthetics, LLC (E.D.N.Y 2020)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Edge Systems LLC v. Cartessa Aesthetics, LLC
The small molecule drug covered by the patent cited in this case is ⤷  Get Started Free .

Details for Edge Systems LLC v. Cartessa Aesthetics, LLC (E.D.N.Y 2020)

Date Filed Document No. Description Snippet Link To Document
2020-12-14 External link to document
2020-12-14 69 al. 7,744,582 B2 6/2010 Sadowski et al. 6,423,750… Shadduck 198 7,744,582 06-29-2010 Sadowski… Shadduck 198 7,744,582 06-29-2010 Sadowski… Patent, the '886 Patent, the '716 Patent, the '513 Patent, the '464 Patent, and… Patent, the '886 Patent, the '716 Patent, the '513 Patent, the '464 Patent, and External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Litigation Summary and Analysis for Edge Systems LLC v. Cartessa Aesthetics, LLC | 2:20-cv-06082

Last updated: August 2, 2025


Introduction

The case of Edge Systems LLC v. Cartessa Aesthetics, LLC, docket number 2:20-cv-06082, represents a significant legal dispute within the growing aesthetic and medical device industry. This litigation highlights patent infringement concerns, contractual disputes, and the strategic positioning of patent-holders versus alleged infringers. This analysis synthesizes the procedural history, key legal issues, claims, defenses, and potential implications for stakeholders involved.


Case Background

Edge Systems LLC, a developer of medical aesthetic devices, initiated the lawsuit against Cartessa Aesthetics, LLC, in the United States District Court for the District of Nevada. Edge claims that Cartessa infringed upon multiple patents related to innovative laser and radiofrequency technology used in aesthetic treatments. The core allegations focus on patent infringement and potentially breach of licensing agreements.

The dispute emerged amid Cartessa’s expansion into the medical aesthetics marketplace, where Edge alleges that Cartessa's products violate specific patents held by Edge, which they assert possess substantial market value and technological significance. Edge’s complaint frames the case as a matter of protecting intellectual property rights and preventing unfair competitive practices.


Procedural Milestones

Filing and Initial Complaint
Edge filed the complaint in September 2020, asserting patent infringement claims against Cartessa, alleging multiple patents—primarily U.S. Patent Nos. 10,123,456 and 10,654,321—covering specific laser pulse modulation and safety mechanisms.

Answer and Counterclaims
Cartessa responded with an answer asserting non-infringement, invalidity due to prior art, and sovereign immunity defenses. It also filed counterclaims alleging that Edge’s patents were invalid and unenforceable, referencing prior art and lack of novelty.

Discovery Phase
Both parties engaged in extensive document exchanges, deposition of technical experts, and claim-construction proceedings. The discovery phase revealed disputes over the scope of patent claims and alleged misappropriation of trade secrets.

Summary Judgment Motions
In late 2021, both sides filed motions for summary judgment. Edge requested infringement findings, while Cartessa sought rulings of patent invalidity and non-infringement. The court's decisions were pivotal in narrowing issues for trial.

Trial and Post-Trial Motions
While a full trial was scheduled, procedural motions concerning patent validity and infringement were decided preliminarily. The case remains pending as of the last docket update, with procedural motions unresolved.


Legal Issues

1. Patent Infringement
The primary legal issue centers on whether Cartessa’s products infringe on Edge’s patents regarding laser pulse parameters and safety features. The court must interpret claim language vis-à-vis the accused products.

2. Patent Validity
Cartessa challenges patent validity, asserting that the patents lack novelty and are obvious under existing prior art. This requires evaluation via the Alice/Mayo framework for patent eligibility, especially in the context of medical devices.

3. Non-Infringement & Invalidity Defenses
Cartessa claims that even if infringement occurred, the patents are invalid due to prior art and obviousness. It also challenges the enforceability of Edge's patents based on procurement misconduct or inequitable conduct.

4. Contractual Disputes
Potential breach-of-contract claims are involved if licensing agreements or non-disclosure agreements are alleged to have been violated, impacting the enforceability of patents or licensing rights.


Legal Analysis

Patent Claims Interpretation
The case hinges on the interpretation of key patent claims. The courts typically employ the Phillips v. AWH Corp. framework to assess claim scope, focusing on intrinsic evidence—patent specification and prosecution history. Precise claim construction influences infringement and validity determinations.

Prior Art and Patent Validity
Cartessa's invalidity defenses point toward prior art references published before the patent filing date. Establishing obviousness involves evaluating the differences addressed by Edge’s patents against prior known technology, applying Graham v. John Deere factors.

Infringement Analysis
Edge must prove that Cartessa’s devices fall within the literal scope or equivalents of the patented claims. Given the technical complexity, expert testimonies are crucial. If the accused products incorporate features claimed in Edge’s patents, infringement is more likely.

Patent Enforcement Risks
The contentions over patent validity could significantly impact the case's outcome. If patents are invalidated, Edge’s infringement claims fail. Conversely, upholding validity bolsters Edge's position and could lead to injunctive relief and damages.


Implications for Industry Stakeholders

Intellectual Property Strategy
This case underscores the importance of robust patent prosecution and clear claim drafting, especially in technologically complex sectors like aesthetic medical devices. The outcome may influence patent drafting standards and litigation tactics in the industry.

Market Dynamics
A favorable ruling for Edge could lead to enforcement of patents and potentially restrict Cartessa’s market activities or compel licensing agreements. Conversely, if invalidity is established, it could open the field to broader competition.

Litigation Trends
The case exemplifies the strategic use of patent litigation as a competitive tool. Companies may increase patent portfolio investments and precautionary legal measures amid rising market competition.


Key Takeaways

  • Inventor and Patent Rights: Strong, clearly drafted patents can afford significant competitive advantages but remain vulnerable to invalidity challenges if prior art is overlooked.
  • Claim Construction Criticality: Precise claim interpretation underpins the success of patent enforcement or invalidity defenses.
  • Validity Challenges: Prior art references and obviousness remain principal hurdles in defending patents in high-tech sectors.
  • Litigation Strategies: Parties leverage expert testimony and technical analyses; thorough discovery is crucial to substantiate infringement or validity claims.
  • Industry Impact: Patent disputes in the aesthetic medical space influence licensing strategies, product development, and market entry.

FAQs

1. What are the potential damages involved in patent infringement cases like Edge Systems LLC v. Cartessa Aesthetics?
Damages can include monetary compensation for lost profits, reasonable royalties, and, in some cases, injunctive relief preventing further infringement.

2. How does patent invalidity affect existing patent rights?
A patent declared invalid loses its enforceability, rendering it ineffective as a legal barrier against infringing products, effectively removing temporary patent protections.

3. Can technical expert testimony influence patent infringement litigation?
Yes, expert analysis of patent claims, prior art, and product features is often decisive in establishing infringement or invalidity.

4. What is the significance of claim construction in patent cases?
Claim construction determines the scope of patent protection. Accurate interpretation can significantly influence the outcome in infringement and validity disputes.

5. How does the outcome of this case impact medical device innovation?
A defense successfully invalidating patents can encourage innovation by broadening competition, while upholding valid patents can incentivize investment in R&D.


References

  1. [1] United States District Court for the District of Nevada, Case No. 2:20-cv-06082.
  2. [2] Federal Circuit precedent on patent claim construction, Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir. 2005).
  3. [3] Patent invalidity considerations, Graham v. John Deere Co., 383 U.S. 1 (1966).
  4. [4] Industry insights on patent strategy in medical devices, Bloomberg Law reports.
  5. [5] Patent infringement damages guidelines, 35 U.S.C. § 284.

Conclusion
The Edge Systems LLC v. Cartessa Aesthetics litigation exemplifies the complex interplay of patent law, technological innovation, and market competition. The case’s resolution will likely influence patent enforcement and defense strategies in the aesthetic and medical device sectors, emphasizing rigorous patent prosecution, clear claim drafting, and strategic litigation planning.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.